Surmodics drops after report on FTC’s view on planned sale to GTCR (SRDX:NASDAQ)

Rate this post


Federal Trade Commission

hapapapa

Medical device manufacturer Surmodics (NASDAQ:SRDX:) decreased by 6% Its planned sale to private equity firm GTCR following a report of a possible opinion from the antitrust regulator.

The Federal Trade Commission may look into the $627 million acquisition of Surmodics (NASDAQ:SRDX:) how

 
Report

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *